Scan Results
Daily timeframeFresenius SE & Co. KGaA operates in the Medical Care Facilities space. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. The $20.68B market capitalization puts FRE.DE squarely in large-cap range for its industry. It operates through Fresenius Kabi and Fresenius Helios segments.
Market Cap
$20.68B
Beta
0.86
P/E (TTM)
13.70
P/E (Fwd)
9.42
EPS (TTM)
$2.68
EPS (Fwd)
$3.90
ROE
7.8%
ROA
3.3%
Cash
$2.06B
Total Debt
$11.91B
Free CF
$1.80B
52W Change
-14.5%
Annual Financials
Cash vs Debt
Fresenius SE & Co. KGaA carries $11.91B in total debt against $2.06B in cash reserves — debt is roughly 5.8x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $1.80B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 7.8%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 3.3% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $21.53B (2022) to $22.87B (2025).
The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Fresenius SE & Co. KGaA and its sector.